A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period that ended September 30, so let’s proceed with the discussion of the hedge fund sentiment on Ocular Therapeutix Inc (NASDAQ:OCUL).
Ocular Therapeutix Inc (NASDAQ:OCUL) investors should be aware of a decrease in enthusiasm from smart money of late. There were 11 hedge funds in our database with OCUL holdings at the end of the second quarter, which fell by 5 during the third quarter. At the end of this article we will also compare OCUL to other stocks including Avenue Income Credit Strategies Fund (NYSE:ACP), Pacific Mercantile Bancorp (NASDAQ:PMBC), and CyberOptics Corporation (NASDAQ:CYBE) to get a better sense of its popularity.
At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.
How are hedge funds trading Ocular Therapeutix Inc (NASDAQ:OCUL)?
At the end of the third quarter, a total of 6 of the hedge funds tracked by Insider Monkey were long this stock, a 45% tumble from the previous quarter. By comparison, 9 hedge funds held shares or bullish call options in OCUL heading into this year, which has fallen by 33% in 2016. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were upping their stakes significantly (or already accumulated large positions).
According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Columbus Circle Investors, holds the biggest position in Ocular Therapeutix Inc (NASDAQ:OCUL). Columbus Circle Investors has a $3.4 million position in the stock. The second most bullish fund manager is Thomas Bailard of Bailard Inc, with a $2.2 million position. Some other hedge funds and institutional investors with similar optimism comprise Brian Ashford-Russell and Tim Woolley’s Polar Capital, Hal Mintz’s Sabby Capital, and Mike Vranos’ Ellington. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds, which is based on the performance of their 13F long positions in non-micro-cap stocks.